Hand holding the newspaper resting on a table with a cup of coffee

Newsroom

Taxonomy Icon
First-in-human Study to Determine Effectiveness of Novel, Non-invasive Therapy for Brain Cancer
  • November 21, 2019
  • Source: Onco'Zine - The International Oncology Network
The Ivy Brain Tumor Center at the Barrow Neurological Institute and SonALASense have signed an strategic agreement to jointly test a new and non-invasive drug-device combination, called sonodynamic therapy or SDT, for the treatment of recurrent glioblastoma.
Taxonomy Icon
Ivy Brain Tumor Center and SonALAsense to Test Novel Drug-Device Combination for Glioblastoma
  • November 21, 2019
The Ivy Brain Tumor Center at the Barrow Neurological Institute, today announced a strategic collaboration with SonALASense to develop and test a new, non-invasive drug-device combination, sonodynamic therapy (SDT), for recurrent glioblastoma through a Phase 0/2 clinical trial.
Taxonomy Icon
Philanthropist Funds Personalized Research Program For Brain Cancer
  • October 30, 2019
  • Source: Your Mark On The World
Catherine Ivy sat down with Devin Thorpe's Your Mark On The World to discuss her personal fight with glioblastoma and how she hopes to shake up the research process with her investment in the Ivy Center's Phase 0 clinical trials.
Taxonomy Icon
Ivy Brain Tumor Center And BridgeBio Subsidiary QED Therapeutics Announce Collaboration To Advance Cancer Research And Treatment Options
  • September 24, 2019
The Ivy Brain Tumor Center at Barrow Neurological Institute, today announced a new collaboration with QED Therapeutics, Inc., a subsidiary of BridgeBio Pharma, Inc., to investigate the FGFR1-3 tyrosine kinase inhibitor, infigratinib, for the treatment of glioblastoma (GBM).
Taxonomy Icon
Social Impact Heroes: “Why Catherine Ivy and the Ivy Foundation have contributed over $91 million to accelerate drug and treatment discovery for brain cancer”
  • September 12, 2019
  • Source: Authority Magazine
Catherine Ivy was recently interviewed for Authority Magazine's latest "Social Impact Heroes" series where she opened up about her 14-year journey to accelerate drug discovery for brain tumor patients, a recent success story from the Ivy Center's Phase 0 clinical trials program, and what our community, society and politicians can do to help address the unmet needs of patients battling aggressive brain tumors.
Taxonomy Icon
Ivy Brain Tumor Center And Salarius Pharmaceuticals Launch Collaborative Partnership To Develop New Cancer Treatment For Glioblastoma
  • August 26, 2019
The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), today announced a collaborative partnership to test Salarius’ therapeutic candidate, Seclidemstat, for the treatment of glioblastoma.
Taxonomy Icon
The Ivy Brain Tumor Center Identifies New Breast Cancer Drug as Possible Glioblastoma Therapy
  • July 26, 2019
  • Source: TrialSiteNews
The Ivy Brain Tumor Center at the Barrow Neurological Institute recently completed a Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali) for the treatment of recurrent glioblastoma. The Ivy recently received $50 million to combat brain cancer. This new drug cocktail represents one of the potential weapons in humankind’s war against this killer disease.
Taxonomy Icon
Glioblastoma Awareness Day Campaign Raises More Than $530K
  • July 26, 2019
Barrow Neurological Foundation led a fundraising effort that raised more than $539,000 for brain cancer research at the Ivy Brain Tumor Center on the first ever Glioblastoma Awareness Day, July 17, 2019.
Taxonomy Icon
Clinical Trial Identifies New Breast Cancer Drug As A Potential Therapy For Glioblastoma
  • July 25, 2019
The Ivy Brain Tumor Center at the Barrow Neurological Institute has released the results of its recent Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali®) for the treatment of recurrent glioblastoma.
Taxonomy Icon
By Targeting Each Patient’s Unique Tumor, Precision Medicine Is Crushing Once-Untreatable Cancers.
  • July 16, 2019
  • Source: Newsweek
Newsweek's cover story examines the rising success of precision medicine to fight once-untreatable tumors and highlights our efforts in using this method to fight glioblastoma where speed and personalization are key.